Logo
Subscribe Now

All Posts by Date

Genentech's Tecentriq Receives the US FDA's Approval as Adjuvant Treatment for Early Non-Small Cell Lung Cancer

Genentech's Tecentriq Receives the US FDA's Approval as Adjuvant Treatment for Early Non-Small Cell Lung Cancer

AbbVie-Skyrizi (risankizumab) Receives CHMP's Positive Opinion for the Treatment of Adults with Active Psoriatic Arthritis in the EU

AbbVie-Skyrizi (risankizumab) Receives CHMP's Positive Opinion for the Treatment of Adults with Active Psoriatic Arthritis in the EU

Boehringer Ingelheim's Cyltezo (biosimilar- adalimumab) Receives the US FDA's sBLA Approval as the 1st Interchangeable Biosimilar for Multiple Chronic Inflammatory Diseases

Boehringer Ingelheim's Cyltezo (biosimilar- adalimumab) Receives the US FDA's sBLA Approval as the 1st Interchangeable Biosimilar for Multiple Chronic Inflammatory Diseas...

Bio-Thera Expands its Partnership with Pharmapark to Commercialize BAT2206 (biosimilar- ustekinumab in Russia and other CIS Countries

Bio-Thera Expands its Partnership with Pharmapark to Commercialize BAT2206 (biosimilar- ustekinumab in Russia and other CIS Countries

Innovent Reports Results of Sintilimab in P-III ORIENT-31 Study for EGFR-Mutated Non squamous Non-Small Cell Lung Cancer

Innovent Reports Results of Sintilimab in P-III ORIENT-31 Study for EGFR-Mutated Non squamous Non-Small Cell Lung Cancer

Ipsen Signs an Exclusive WW Collaboration with Accent to Develop and Commercialize METTL3 Program

Ipsen Signs an Exclusive WW Collaboration with Accent to Develop and Commercialize METTL3 Program

Image

Stay Connected

We Have a Viewership of 1,00,000 + Views

Join the PharmaShot Family

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2021 PharmaShots - All Rights Reserved.